Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Future of Sanitation: Strategies for COVID 2.0 and Beyond

COVID-19 – remember when that was still a thing? Everyone thought for sure they’d be saying that by now. But, with daily cases in the U.S. reaching all-time highs and a vaccine rollout that will take much longer than desired, getting things back to a semblance of normalcy isn’t happening anytime soon. And what…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

COVID-19 – remember when that was still a thing? Everyone thought for sure they’d be saying that by now. But, with daily cases in the U.S. reaching all-time highs and a vaccine rollout that will take much longer than desired, getting things back to a semblance of normalcy isn’t happening anytime soon.

And what does normalcy even look like in a COVID 2.0 world, anyway? What are the continuing safety measures businesses, hospitals and schools need to do to keep people safe now and into the future? John Shanahan, President and CEO of Ionogen, and Dr. Jack Lacey, retired CMO of the University of Tennessee’s Medical Center, spoke about the situation and how air sanitation can help keep spaces COVID-free.

New COVID variants are a reminder that the battle against the virus will be a lengthy one, and people need every weapon they can to fight it.

“COVID 1, COVID 2, what makes this virus unique is its ability to hang in the air,” Shanahan said. “We now know we have to take a responsible approach to cleaning the air.”

The bottom line is, even if everything else about an indoor space is clean and sanitized, if the air inside isn’t, COVID can travel and spread.

“COVID-19 most commonly spreads through close human contact and, specifically, through breathing and respiratory droplets,” Dr. Lacey said. “We know that the larger droplets can fall out of the air within the six feet we’re told to distance ourselves, but the much smaller droplets and viral particles can hang in the air for minutes to hours.”

Ionogen’s ionpure line of safe, non-hazardous sanitation products can help fight the coronavirus in the air and on surfaces to make spaces safer for people in facilities of all industries and settings.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512